Division of Molecular Radiation Biology
Look Back into the Future
Bench to Bedside & Back
Next Generation of Clinicians
Adam Dicker, M.D., Ph.D.
– Professor, Chairman and Director, Experimental Radiation Oncology Division Bo Lu, M.D., Ph.D.
– Professor, Director, Division of Molecular Radiation Biology Dennis B. Leeper, Ph.D.
– Professor and Founding Director Ronald A. Coss, Ph.D.
– Professor Ullrich Rodeck, M.D.
– Professor of Dermatology Phyllis R. Wachsberger, Ph.D.
– Assistant Professor Richard Lawrence, M.D.
– Assistant Professor Qing Ren, M.D., Ph.D.
Adjunct Faculty George Iliakis, Ph.D.
– Professor, University of Essen, DL Andrew J. Milligan, Jr., Ph.D.
– Professor, President of Bionix Medical Technologies Ya Wang, M.D., Ph.D.
– Professor, Emory University Randy Burd, Ph.D.
– Assistant Professor, University of Arizona
This research is based on a new paradigm emerging in oncology; the only truly effective way to prevent or treat cancer is to selectively target cancer stem cells (CSC). This view is supported by mounting evidence that overpopulation of CSC drives tumor initiation & progression and that CSCs are relatively resistant to conventional therapies. Our goal is to identify mechanisms that regulate normal stem cell (SC) population size in tissues, and to determine how dysregulation of these mechanisms leads to stem cell overpopulation and cancer development. Understanding these mechanisms would provide a rationale for development of therapeutics that target and eliminate CSC.